Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To determine the anatomical and functional outcome after injection of bevacizumab (Avastin, Genentech) in eyes with retinal angiomatous proliferation (RAP).
Prospective interventional case series.
Sixteen eyes of 16 consecutive patients with visual loss due to RAP underwent intravitreal injections of 1.25 mg (0.05 ml) bevacizumab. Best corrected visual acuity testing, fluorescein and ICG-angiography as well as OCT imaging were performed at baseline and at each follow-up visit within a 3-month period.
Mean visual acuity pre-injection was 0.68 ± 0.36 logMAR (n = 16), mean reading ability 0.58 ± 0.26 logRAD (n = 11). Far vision increased significantly by a mean of 1.7 ± 2 lines 4 weeks after the injection (p = 0.004), as did reading (0.6 ± 2.3 lines, p > 0.05). Both remained stable up to 3 months. Central retinal thickness decreased from 367 ± 112 μm (mean±SD) to 272 ± 123 μm 3 months after injection (p = 0.006). Leakage decreased angiographically in 12 eyes (75%) and remained stable in four eyes (25%). Re-injection of bevacizumab within the 3-month follow-up period was performed once in eight eyes, and twice in one eye. No adverse events were observed.
Intravitreal bevacizumab (Avastin) resulted in a reduction of leakage, intra- and subretinal fluid. An increase in visual acuity was seen already 4 weeks after first injection. However, a complete occlusion of feeder vessels could not be achieved within this 3-month period. Randomized clinical trials would be required to evaluate dose and frequency of injections and possible beneficial effects of combination therapies, as well as the long-term results.
- Kuhn D, Meunier I, Soubrane G et al (1995) Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol 11:1392–1398
- Boscia F, Furino C, Sborgia L et al (2004) Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 138:1077–1079 CrossRef
- Nicolo M, Ghiglione D, Lai S et al (2006) Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 244:1336–1338 CrossRef
- Bottoni F, Romano M, Massacesi A et al (2006) Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:1528–1533 CrossRef
- Freund KB, Klais CM, Eandi CM et al (2006) Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 124:487–492 CrossRef
- Smithen LM, Ober MD, Maranan L et al (2004) Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138:740–743 CrossRef
- Jonas J, Heatley G, Spaide R et al (2005) Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 14:168–171 CrossRef
- Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816 CrossRef
- Medienmitteilung Novartis. Preliminary data from second pivotal Phase III study showed Lucentis maintained or improved vision in 95 percent of patients with age-related macular degeneration. Basel, 7. November 2005
- Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390 CrossRef
- Yannuzzi LA, Negrao S, Iida T et al (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416–434 CrossRef
- Radner W, Willinger U, Obermayer W et al (1998) Eine neue Lesetafel zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit. Klin Monatsbl Augenheilkd 213:174–181 CrossRef
- Stifter E, Konig F, Lang T et al (2004) Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. Graefes Arch Clin Exp Ophthalmol 242:31–39 CrossRef
- Schachat AP, Chambers WA, Liesegang TJ, Albert DA (2003) Safe and effective. Ophthalmology 110:2073–2074 CrossRef
- Slakter JS, Yannuzzi LA, Schneider U et al (2000) Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 107:742–753 CrossRef
- Klais CM, Eandi CM, Ober MD et al (2006) Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study. Retina 26:773–779 CrossRef
- Lafaut BA, Aisenbrey S, Vanden Broecke C et al (2000) Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration. Br J Ophthalmol 84(11):1269–1274 CrossRef
- Strauss O (2005) The retinal pigment epithelium in visual function. Physiol Rev 85:845–881 CrossRef
- Blaauwgeers HG, Holtkamp GM, Rutten H et al (1999) Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155:421–428
- Jablonski MM, Tombran-Tink J, Mrazek DA et al (2001) Pigment epithelium derived factor supports normal Muller cell development and glutamine synthetase expression after removal of the retinal pigment epithelium. Glia 35:14–25 CrossRef
- Becerra SP, Fariss RN, Wu YQ et al (2004) Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res 78:223–234 CrossRef
- Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation
Graefe's Archive for Clinical and Experimental Ophthalmology
Volume 245, Issue 11 , pp 1597-1602
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Retinal angiomatous proliferation
- Age-related macular degeneration
- Anti-VEGF therapy
- Industry Sectors
- Author Affiliations
- 1. Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Cologne, Germany
- 2. Department of Ophthalmology, Unviversity of Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany
- 3. Department of Ophthalmology, Tagesklinik Universitaetsallee, Bremen, Germany